Edgewise Therapeutics, Inc. EWTX
Edgewise Therapeutics, Inc. (Nasdaq: EWTX) is a cardio-renal-metabolic drug developer. Its lead program, EDG-7500, is in Phase 2 for Obstructive and nonobstructive hypertrophic cardiomyopathy (HCM). Its next catalyst on record is EDG-7500: Initiation of Phase 3 trial in HCM (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: EDG-7500 — Initiation of Phase 3 trial in HCM (Q4 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| EDG-7500 (cardiac sarcomere modulator) | Hypertrophic cardiomyopathy | small molecule | Phase 2 |
| EDG-15400 | Heart failure with preserved ejection fraction (future target); Phase 1 in healthy adults | small molecule | Phase 1 |
| EDG-003 cardiometabolic discovery program | Cardiometabolic | small molecule | Pre-clinical |
Recent results and decisions
- May 7, 2026positive Open-label extension MESA data presented at MDA showed sustained functional (NSAA) stabilization on sevasemten for up to 3.5 years versus decline expected from natural history.
At the 2026 MDA Clinical and Scientific Conference, the Company presented long-term data from MESA showing participants on sevasemten experienced stabilization of function up to 3.5 years in marked contrast to the functional decline expected from Becker natural history data.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.